A Case-Based Approach to CLL and MCL: Novel Therapies and Transplant Options
Using a case-based format and the latest research, experts address the clinical management of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) and discuss both frontline and salvage therapies. Such therapies will include conventional chemotherapy, novel agents as well as transplant approaches. For CLL, what is the risk-adapted sequence for treatment and who can benefit from earlier and more aggressive therapeutic interventions, including hematopoietic cell transplantation (HCT)? For MCL, what are the optimal therapeutic approaches for this challenging disease using standard agents, novel approaches, and HCT?
This activity is intended for Hematologists and Oncologists who treat patients with CLL and MCL.
- Identify biologic and clinical factors and current recommendations in selecting risk-adapted treatment for CLL
- Determine timing of transplant for CLL based on patient risk, disease and molecular factors
- Evaluate outcomes for current therapeutic approaches to MCL
- Compare the risks and benefits of MCL treatment approaches, and how timing of transplant and clinical patient characteristics affects outcomes
Thomas J. Kipps, M.D., Ph.D.
Moores Cancer Center, University of California-San Diego, La Jolla, California
Peter Dreger, M.D.
University of Heidelberg, Heidelberg, Germany
Ajay Gopal, M.D.
University of Washington, Seattle, Washington
Julie Vose, M.D., MBA
University of Nebraska Medical Center, Omaha, Nebraska
Willis Navarro, M.D. (moderator)
National Marrow Donor Program, Minneapolis, Minnesota
If you have any questions regarding this activity, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail email@example.com
1 To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.